{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:34:47Z","timestamp":1765888487517,"version":"build-2065373602"},"reference-count":45,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T00:00:00Z","timestamp":1606608000000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,11,8]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Neuromyelitis optica spectrum disorders (NMOSD) is an inflammatory and heterogeneous astrocyte disorder of the central nervous system with the characteristic of higher incidence in women and Asian people. Most patients with NMOSD have a course of recurrence and remission that is prone to cause paralysis and blindness. Several studies have confirmed the efficacy and promising prospect of mycophenolate mofetil (MMF) in the treatment of NMOSD. Yet its therapeutic effect and safety are controversial. Although there has been two published literature that is relevant to the topic of this study, both of them have certain defects, and they can only provide answers about the efficacy or safety of MMF in the treatment of NMOSD from partial perspectives or conclusions. This research aims to perform a direct and comprehensive systematic review and meta-analysis to evaluate MMF\u2019s effectiveness and safety in treating NMOSD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>This systematic review will cover all comparative researches, from randomised controlled trials to cohort studies, and case\u2013control study. A relevant literature search will be conducted in PubMed, Web of Science, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, China Science and Technology Journal Database and Chinese Biomedical Literature Database from their inception to 31 June 2020. We will also search registers of clinical trials, potential grey literature and abstracts from conferences. There are no limits on language and publication status. The reporting quality and risk of bias will be assessed by two researchers independently. Expanded Disability Status Scales and annualised relapse rate will be evaluated as the primary outcome. The secondary outcomes will consist of the frequency and severity of adverse events, best-corrected visual acuity, relapse-free rate and time to the next attack. A meta-analysis will be performed using RevMan V.5.3 software provided by the Cochrane Collaboration and Stata V.12.0.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>Because the data used for this systematic review will be exclusively extracted from published studies, ethical approval and informed consent of patients will not be required. The systematic review will be published in a peer-reviewed journal, presented at conferences and will be shared on social media platforms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42020164179.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-040371","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T16:10:52Z","timestamp":1606752652000},"page":"e040371","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2342-268X","authenticated-orcid":false,"given":"Mengyu","family":"Han","sequence":"first","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine, Beijing, China"},{"name":"Department of Ophthalmology, China\u2013Japan Friendship Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luqi","family":"Nong","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine, Beijing, China"},{"name":"Department of Ophthalmology, China\u2013Japan Friendship Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine, Beijing, China"},{"name":"Department of Ophthalmology, China\u2013Japan Friendship Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China\u2013Japan Friendship Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Meng","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine, Beijing, China"},{"name":"Department of Ophthalmology, China\u2013Japan Friendship Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Qin","sequence":"additional","affiliation":[{"name":"Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China\u2013Japan Friendship Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China\u2013Japan Friendship Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"2025101811112730000_10.11.e040371.1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17030273","article-title":"The immunology of neuromyelitis Optica-Current knowledge, clinical implications, controversies and future perspectives","volume":"17","author":"Jasiak-Zatonska","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2025101811112730000_10.11.e040371.2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00415-012-6594-3","article-title":"On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica","volume":"260","author":"Jarius","year":"2013","journal-title":"J Neurol"},{"key":"2025101811112730000_10.11.e040371.3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2016.06.002","article-title":"The role of AQP4 in neuromyelitis optica: more answers, more questions","volume":"298","author":"Yang","year":"2016","journal-title":"J Neuroimmunol"},{"key":"2025101811112730000_10.11.e040371.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8"},{"key":"2025101811112730000_10.11.e040371.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"2025101811112730000_10.11.e040371.6","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515572406"},{"key":"2025101811112730000_10.11.e040371.7","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314839"},{"key":"2025101811112730000_10.11.e040371.8","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/1352458518792430","article-title":"A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia","volume":"25","author":"Viswanathan","year":"2019","journal-title":"Mult Scler"},{"key":"2025101811112730000_10.11.e040371.9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317321"},{"key":"2025101811112730000_10.11.e040371.10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.1107"},{"key":"2025101811112730000_10.11.e040371.11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a6cb5c"},{"key":"2025101811112730000_10.11.e040371.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.034"},{"key":"2025101811112730000_10.11.e040371.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.08.004"},{"key":"2025101811112730000_10.11.e040371.14","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.141"},{"key":"2025101811112730000_10.11.e040371.15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2025101811112730000_10.11.e040371.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7169-7"},{"key":"2025101811112730000_10.11.e040371.17","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514525870"},{"key":"2025101811112730000_10.11.e040371.18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","article-title":"Analysis of the treatment of neuromyelitis optica","volume":"351","author":"Torres","year":"2015","journal-title":"J Neurol Sci"},{"key":"2025101811112730000_10.11.e040371.19","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","article-title":"Rituximab in the treatment of neuromyelitis optica: a multicentre Italian observational study","volume":"263","author":"Annovazzi","year":"2016","journal-title":"J Neurol"},{"key":"2025101811112730000_10.11.e040371.20","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616632653"},{"key":"2025101811112730000_10.11.e040371.21","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.175"},{"key":"2025101811112730000_10.11.e040371.22","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol"},{"key":"2025101811112730000_10.11.e040371.23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/WNF.0000000000000131","article-title":"The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in Western China","volume":"39","author":"Chen","year":"2016","journal-title":"Clin Neuropharmacol"},{"key":"2025101811112730000_10.11.e040371.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-018-1056-x","article-title":"Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study","volume":"18","author":"Jiao","year":"2018","journal-title":"BMC Neurol"},{"key":"2025101811112730000_10.11.e040371.25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur J Neurol"},{"key":"2025101811112730000_10.11.e040371.26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J Neurol Sci"},{"key":"2025101811112730000_10.11.e040371.27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.msard.2019.08.009","article-title":"Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis","volume":"35","author":"Huang","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2025101811112730000_10.11.e040371.28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.msard.2019.05.011","article-title":"Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"33","author":"Espiritu","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2025101811112730000_10.11.e040371.29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.msard.2018.12.038","article-title":"Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder","volume":"28","author":"Zhou","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2025101811112730000_10.11.e040371.30","doi-asserted-by":"crossref","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","article-title":"Evaluation of efficacy and tolerability of first-line therapies in NMOSD","volume":"94","author":"Poupart","year":"2020","journal-title":"Neurology"},{"key":"2025101811112730000_10.11.e040371.31","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-019-09649-7","article-title":"Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"267","author":"Shi","year":"2020","journal-title":"J Neurol"},{"key":"2025101811112730000_10.11.e040371.32","doi-asserted-by":"crossref","unstructured":"Stroup DF , Berlin JA , Morton SC , et al . Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA;283:2008\u201312.","DOI":"10.1001\/jama.283.15.2008"},{"key":"2025101811112730000_10.11.e040371.33","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2025101811112730000_10.11.e040371.34","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"2025101811112730000_10.11.e040371.35","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"2025101811112730000_10.11.e040371.36","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"2025101811112730000_10.11.e040371.37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jneuroim.2019.04.007","article-title":"Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: a systematic review","volume":"332","author":"Enriquez","year":"2019","journal-title":"J Neuroimmunol"},{"key":"2025101811112730000_10.11.e040371.38","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/262350"},{"key":"2025101811112730000_10.11.e040371.39","doi-asserted-by":"publisher","DOI":"10.3310\/hta21410"},{"key":"2025101811112730000_10.11.e040371.40","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-3-37","article-title":"Evaluation of the Cochrane collaboration\u2019s tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation","volume":"15","author":"Savovi\u0107","year":"2014","journal-title":"Syst Rev"},{"key":"2025101811112730000_10.11.e040371.41","unstructured":"Wells G , Shea B , O'Connell D , et al . The Newcastle\u2013Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Mult Scler;13:968\u201374."},{"key":"2025101811112730000_10.11.e040371.42","unstructured":"The Nordic Cochrane collaboration . Review manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane collaboration, 2008."},{"key":"2025101811112730000_10.11.e040371.43","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-017-0630-4","article-title":"Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes","volume":"6","author":"Chen","year":"2017","journal-title":"Syst Rev"},{"key":"2025101811112730000_10.11.e040371.44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025101811112730000_10.11.e040371.45","doi-asserted-by":"crossref","DOI":"10.1186\/s12950-017-0174-3","article-title":"Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome","volume":"14","author":"Shih","year":"2017","journal-title":"J Inflamm"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-040371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:11:34Z","timestamp":1760811094000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-040371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,30]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjopen-2020-040371"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-040371","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}